サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：肺炎治療薬の世界市場：市場規模 - 治療薬別、流通チャネル別、年齢層別、感染タイプ別、地域別展望、競合戦略、セグメント別予測（～2032年）
市場調査レポート
商品コード
1159579

肺炎治療薬の世界市場：市場規模 - 治療薬別、流通チャネル別、年齢層別、感染タイプ別、地域別展望、競合戦略、セグメント別予測（～2032年）

Pneumonia Therapeutics Market Size- By Therapeutics, By Distribution Channel, By Age Group, By Infection Type - Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日: | 発行: SPER Market Research Pvt. Ltd. | ページ情報: 英文 256 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.53円
肺炎治療薬の世界市場：市場規模 - 治療薬別、流通チャネル別、年齢層別、感染タイプ別、地域別展望、競合戦略、セグメント別予測（～2032年）
出版日: 2022年11月18日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 256 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の肺炎治療薬の市場規模は、2032年までに426億2,000万米ドルに達し、CAGRで8.3%の成長が予測されています。

肺炎の有病率の増加により、肺炎治療薬は、世界市場を拡大させる重要な要因となっています。また、予測期間中、市中肺炎の頻度の増加が、市場拡大に拍車をかけると予想されます。一方で、医薬品やワクチンに厳しい規則が定められていることは、市場拡大の抑制要因となることが予想されます。

当レポートでは、世界の肺炎治療薬市場について調査し、市場力学、市場変数と見通し、治療薬・流通チャネル・年齢層・感染タイプ・地域別の市場分析、企業プロファイル等に関する情報を提供しています。

目次

第1章 イントロダクション

  • 調査範囲
  • 市場セグメント分析

第2章 調査手法

  • 調査データソース
  • 市場規模の推定
  • データの三角測量

第3章 エグゼクティブサマリー

第4章 市場力学

  • 促進要因、抑制要因、機会、課題の分析
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • 世界の肺炎治療薬市場におけるCOVID-19の影響

第5章 市場変数と見通し

  • SWOT分析
    • 強み
    • 弱み
    • 機会
    • 脅威
  • PESTEL分析
    • 政治情勢
    • 経済情勢
    • 社会情勢
    • 技術情勢
    • 環境情勢
    • 法的情勢
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入者の脅威
    • 競合企業間の敵対関係
  • ヒートマップ分析

第6章 世界の肺炎治療薬市場：治療薬別、2019年～2032年（100万米ドル）

  • 予防ワクチン
  • 治療薬
    • 抗菌薬
    • 抗ウイルス薬
    • 抗真菌薬

第7章 世界の肺炎治療薬市場：流通チャネル別、2019年～2032年（100万米ドル）

  • 病院
  • 医薬品販売店
  • その他

第8章 世界の肺炎治療薬市場：年齢層別、2019年～2032年（100万米ドル）

  • 小児
  • 成人
  • 高齢者

第9章 世界の肺炎治療薬市場：感染タイプ別、2019年～2032年（100万米ドル）

  • 院内肺炎（HAP）
  • 市中肺炎（CAP）
  • 人工呼吸器関連肺炎（VAP）

第10章 世界の肺炎治療薬市場：地域別、2019年～2032年（100万米ドル）

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • その他のアジア太平洋
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米
  • 中東・アフリカ
    • サウジアラビア王国
    • アラブ首長国連邦
    • その他の中東・アフリカ

第11章 企業プロファイル

  • Abbott Laboratories
    • 企業概要
    • 財務見通し
    • 製品概要
    • 最近の開発
  • Bayer AG
  • Eli Lilly & Company
  • Glaxosmithkline Plc.
  • Lupin Pharmaceuticals, Inc.
  • Merck KGAA
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals Industries Limited
目次
Product Code: HLCA2217

Global Pneumonia Therapeutics Market Overview:

According to SPER Market Research, the Global Pneumonia Therapeutics Market is estimated to reach USD 42.62 billion by 2032 with a CAGR of 8.3%.

An infection that affects the lower respiratory system is pneumonia. Additionally, pneumonia exhibits symptoms including shortness of breath, fever, chest discomfort, nausea, and vomiting. Alveoli, the lungs' air sacs, are filled with fluid or pus in pneumonia, which results in inflammation. It is frequently found in children and the elderly and is mostly brought on by microorganisms including fungi, bacteria, viruses, and parasites. It mainly affects persons with low immune systems.

The increased prevalence of pneumonia is a significant factor driving the expansion of the global market for therapies treating the condition. Additionally, throughout the anticipated period, an increase in the frequency of community-acquired pneumonia is anticipated to fuel market expansion. Additionally, it is anticipated that an increase in product releases following FDA clearance would assist the sector to generate the most income. Additionally, it is anticipated that a rise in clinical trials for the R&D of vaccines and medicinal compounds would support industrial expansion in the next years. The establishment of strict rules for pharmaceuticals and vaccines, however, impedes market expansion.

Impact of COVID-19 on the Global Pneumonia Therapeutics Market

On January 30, 2021, the World Health Organization designated the COVID-19 outbreak a public health emergency of global significance. A person with COVID-19 is especially vulnerable to pneumonia, which can result in wheezing and an accumulation of mucus in the alveoli. This is anticipated to fuel the market for pneumonia treatments. Additionally, it is anticipated that growth in R&D for the treatment of pneumonia associated with COVID-19 would help the market to produce significant revenue throughout the projection period. However, the COVID-19 shortage of workers as well as resource restrictions are anticipated to have a detrimental effect on the industry's growth throughout the projection period. In addition, the industry expansion has been slowed by the installation of strict government restrictions governing lockdown. Additionally, it is urgent to develop fresh products that can aid in the fight against COVID-19. Because of this, the market for pneumonia treatments is expected to produce more money throughout the forecast period.

Scope of the Report:

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Access, By Component, By Type, By End User

Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered Atos SE, Alioth LLC, Cardcom Technology, CardLogix Corporation, CPI Card Group, Eastcompeace, Fingerprint Cards AB, Gemalto NV, Giesecke & Devrient, HID Global Corporation, IDEMIA, Infineon Technologies AG., Texas Instruments, Watchdata Technologies.

Global Pneumonia Therapeutics Market Segmentation:

By Therapeutics: Based on the Therapeutics, Global Pneumonia Therapeutics Market is segmented as; Prevention Vaccines, Treatment Drugs {Antibacterial Drugs (Macrolide, Quinolones, Aminopenicillins, Macrolides, B-lactamase inhibitors, Cephalosporins, Tetracyclines, Glycopeptide antibiotics, Carbapenems, Others), Antiviral Drugs, Antifungal Drugs}.

By Distribution Channel: Based on the Distribution Channel, Global Pneumonia Therapeutics Market is segmented as; Hospitals, Pharmaceutical Stores, Others.

By Age Group: Based on the Age Group, Global Pneumonia Therapeutics Market is segmented as; Pediatric, Adult and Geriatric.

By Infection Type: Based on the Infection Type, Global Pneumonia Therapeutics Market is segmented as; Hospital-acquired pneumonia, Community-acquired pneumonia, Ventilator-associated pneumonia.

By Region: Due to rising geriatric populations, an ageing population, and an increase in both adult and paediatric multidrug resistance, North America had the largest revenue share and is predicted to keep it throughout the forecast period. These factors reinforce the need for development and rising R&D activities.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Pneumonia Therapeutics Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Pneumonia Therapeutics Market, By Therapeutics, 2019-2032 (USD Million)

  • 6.1 Prevention Vaccines
  • 6.2 Treatment Drugs
    • 6.2.1 Antibacterial Drugs
      • 6.2.1.1 Macrolide
      • 6.2.1.2 Quinolones
      • 6.2.1.3 Aminopenicillins
      • 6.2.1.4 Macrolides
      • 6.2.1.5 B-lactamase inhibitors
      • 6.2.1.6 Cephalosporins
      • 6.2.1.7 Tetracyclines
      • 6.2.1.8 Glycopeptide antibiotics
      • 6.2.1.9 Carbapenems
      • 6.2.1.10 Others
    • 6.2.2 Antiviral Drugs
    • 6.2.3 Antifungal Drugs

7. Global Pneumonia Therapeutics Market, By Distribution Channel, 2019-2032 (USD Million)

  • 7.1 Hospitals
  • 7.2 Pharmaceutical Stores
  • 7.3 Others

8. Global Pneumonia Therapeutics Market, By Age Group, 2019-2032 (USD Million)

  • 8.1 Pediatric
  • 8.2 Adult
  • 8.3 Geriatric

9. Global Pneumonia Therapeutics Market, By Infection Type, 2019-2032 (USD Million)

  • 9.1 Hospital-acquired pneumonia (HAP)
  • 9.2 Community-acquired pneumonia (CAP)
  • 9.3 Ventilator-associated pneumonia (VAP)

10. Global Pneumonia Therapeutics Market, By Region, 2019-2032 (USD Million)

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 United Kingdom
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 Australia
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Rest of South America
  • 10.5 Middle East & Africa
    • 10.5.1 Kingdom of Saudi Arabia
    • 10.5.2 United Arab Emirates
    • 10.5.3 Rest of Middle East & Africa

11. Company Profiles

  • 11.1 Abbott Laboratories
    • 11.1.1 Company details
    • 11.1.2 Financial outlook
    • 11.1.3 Product summary
    • 11.1.4 Recent developments
  • 11.2 Bayer AG
    • 11.2.1 Company details
    • 11.2.2 Financial outlook
    • 11.2.3 Product summary
    • 11.2.4 Recent developments
  • 11.3 Eli Lilly & Company
    • 11.3.1 Company details
    • 11.3.2 Financial outlook
    • 11.3.3 Product summary
    • 11.3.4 Recent developments
  • 11.4 Glaxosmithkline Plc.
    • 11.4.1 Company details
    • 11.4.2 Financial outlook
    • 11.4.3 Product summary
    • 11.4.4 Recent developments
  • 11.5 Lupin Pharmaceuticals, Inc.
    • 11.5.1 Company details
    • 11.5.2 Financial outlook
    • 11.5.3 Product summary
    • 11.5.4 Recent developments
  • 11.6 Merck KGAA
    • 11.6.1 Company details
    • 11.6.2 Financial outlook
    • 11.6.3 Product summary
    • 11.6.4 Recent developments
  • 11.7 Novartis AG
    • 11.7.1 Company details
    • 11.7.2 Financial outlook
    • 11.7.3 Product summary
    • 11.7.4 Recent developments
  • 11.8 Pfizer, Inc.
    • 11.8.1 Company details
    • 11.8.2 Financial outlook
    • 11.8.3 Product summary
    • 11.8.4 Recent developments
  • 11.9 Sanofi S.A.
    • 11.9.1 Company details
    • 11.9.2 Financial outlook
    • 11.9.3 Product summary
    • 11.9.4 Recent developments
  • 11.10 Teva Pharmaceuticals Industries Limited
    • 11.10.1 Company details
    • 11.10.2 Financial outlook
    • 11.10.3 Product summary
    • 11.10.4 Recent developments